Additional file 1 of Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity

Additional file 1: Fig. S1. CircMET RNA in silico analysis. Fig. S2. circMET expression and cellular localization. Fig. S3. Generation and characterization of HCC827 and WiDr drug-resistant subpopulations. Fig.S4. CircMET evaluation reveals HER/MET codependency and mirrors combination therapy response in vitro. Fig.S5. Heatmap of concordance among assays applied to the primary samples. Table S1. Cancer cell lines assessed for MET and circMET expression, with indication of MET amplification status. Table S2. Clinical information of the primary samples included in the study. Table S3. Summary of the somatic alterations detected with Guardant360 Biopsy-Free Tumor Sequencing in case #5 upon relapse to osimertinib. Table S4. List of primers and probes.